Sorrento Therapeutics (NSDQ:SRNE) revealed that its late-stage preclinical main protease inhibitor STI-1558 inhibited omicron virus entry and replication in cell-based assays. Prior research indicates that STI-1558 offers broad-spectrum activity against SARS-CoV-2. STI-1558 is distinct from Pfizer’s SARS-CoV-2 drug Paxlovid (nirmatrelvir), which pairs the SARS-CoV-2-3CL protease inhibitor PF-07321332 with ritonavir, which works as a pharmacokinetic enhancer.…
Brazilian regulators authorize Sorrento Phase 2 clinical trial of COVI-MSC in COVID-19 long-haulers
Sorrento Therapeutics (NSDQ:SRNE) has received the go-ahead from the Brazilian Health Regulatory Agency (ANVISA) for a Phase 2a study involving its COVI-MSC allogeneic adipose-derived mesenchymal stromal cells. The company hopes the experimental treatment will benefit patients with so-called “long COVID,” a syndrome linked with a variety of symptoms ranging from fatigue to pulmonary compromise. The…